Dr. med. Alvaro Moreira

Department of Dermatology

Senescence markers: Predictive for response to checkpoint inhibitors (2019) Moreira A, Gross S, Kirchberger MC, Erdmann M, Schuler G, Heinzerling L Journal article Predicting the response of uveal melanoma to immunotherapy with MRI assessments (2019) Moreira A, Saake M, Schuler G, Heinzerling L Conference contribution Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors (2019) Moreira A, Loquai C, Pfoefer C, Kaehler KC, Knauss S, Heppt MV, Gutzmer R, et al. Journal article Eosinophil-cationic protein: A novel liquid prognostic biomarker in melanoma (2018) Moreira A, Krueckel A, Schuler G, Heinzerling L Conference contribution Anti-PD-1 Therapy in SUFU mutant Patients with Gorlin-Goltz Syndrome (2018) Moreira A, Kirchberger MC, Toussaint F, Erdmann M, Schuler G, Heinzerling L Conference contribution Dry Mouth under Immune Checkpoint Inhibitors: an Analysis of 29 Patients from 10 German Skin Cancer Centers (2018) Hensen J, Thoms KM, Kaehler K, Gutzmer R, Zimmer L, Zacher M, Alter M, et al. Conference contribution Neuromuscular Side Effects of Immune Checkpoint Inhibitors (2018) Moreira A, Loquai C, Knauss S, Gutzmer R, Dimitriou F, Meier F, Heppt M, et al. Conference contribution Hyponatremia and Nephritis - Rare Side Effects of Checkpoint Inhibitors in Patients with metastatic Melanoma (2018) Mitzel-Rink H, Hassel J, Berking C, Gutzmer R, Heinzerling L, Majenka P, Meier F, et al. Conference contribution Eosinophilic Fasciitis by Treatment with Checkpoint Inhibitors in metastatic Melanoma (2018) Toussaint F, Erdmann M, Moreira A, Kirchberger MC, Schuler G, Heinzerling L Conference contribution Expression of Senescence Markers - Is Predictive for Immune Therapy with Checkpoint Inhibitors? (2018) Moreira A, Gross S, Kirchberger MC, Erdmann M, Schuler G, Heinzerling L Conference contribution